Roche to launch another Elevidys study, eying EU approval
Roche is launching a new global phase 3 trial for the controversial Duchenne muscular dystrophy gene therapy Elevidys…
Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies
Roche is licensing out part of its cancer platform to Chinese biotech Innovent Biologics. Innovent gains nonexclusive access…
Roche inks $1.5B Poseida buyout to land off-the-shelf CAR-Ts
Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, which…
Genentech scraps $2B cell therapy pact
Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy…
Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts
Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO has told Fierce Biotech…
Has Novartis’ T-Charge push been overtaken by in vivo CAR-Ts?
It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But…
Elevidys fallout hasn’t dented Roche’s hopes for gene therapies
The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the…